Brief: Glaukos Announces FDA Approval Of iDose TR

Glaukos

14/12/2023 12:38

Dec 14 (Reuters) - Glaukos Corp  GKOS.N :
    * GLAUKOS ANNOUNCES FDA APPROVAL OF IDOSE® TR (TRAVOPROST
INTRACAMERAL IMPLANT)
    * : INTENDS TO COMMENCE INITIAL COMMERCIAL LAUNCH ACTIVITIES
FOR
IDOSE TR IN LATTER PART OF Q1 OF 2024
    * :  INTRODUCES PRELIMINARY 2024 NET SALES GUIDANCE RANGE OF
$350
MILLION TO $360 MILLION
    * : REAFFIRMS ITS 2023 NET SALES RANGE OF $307 MILLION TO
$310
MILLION
    * FY2024 REVENUE VIEW $348.6 MILLION -- LSEG IBES DATA
    * FY2023 REVENUE VIEW $309.1 MILLION -- LSEG IBES DATA

Source text for Eikon:  ID:nBw3fL4yDa 
Further company coverage:  GKOS.N 

 ((Reuters.Briefs@thomsonreuters.com;))